75 Pre-clinical research suggests that GZD824, also known as olverembatinib, could become a viable therapeutic option for endometrial cancer (EC), one of the few cancers with rising mortality rates globally. This multi-kinase inhibitor demonstrated promising results in targeting various pathways associated with tumour progression and resistance to conventional treatments. The findings were published in the journal Cancer Medicine. Endometrial cancer is the sixth most prevalent malignancy worldwide, with limited options for advanced or recurrent cases. Current therapies, such as carboplatin-paclitaxel chemotherapy, have shown mixed success, particularly in high-risk histological subtypes like serous and clear-cell tumours. The lack of effective treatment for p53 wild-type molecular subtypes further underscores the urgency of identifying new therapeutic avenues. GZD824, originally developed as a BCR-ABL inhibitor for chronic myeloid leukaemia, has shown broader applications in oncology due to its ability to target receptor tyrosine kinases, including ROR1. This receptor plays a significant role in endometrial cancer progression. Pre-clinical trials involving GZD824 assessed its impact on seven endometrial cancer cell lines and non-cancerous models. Researchers observed significant inhibition of cancer cell proliferation, migration, and invasion, highlighting its potential as a tumour-specific agent. The study revealed that GZD824 modulates key signalling pathways such as PI3K-AKT, GCN2-ATF4, and epithelial-mesenchymal transition (EMT). In ROR1-positive cell lines, the drug induced a mesenchymal-to-epithelial transition, reducing metastatic capabilities. Additionally, it suppressed stress adaptation mechanisms in cancer cells, enhancing their sensitivity to nutrient deprivation and immune system attacks. RNA sequencing further supported these findings, with significant changes in gene expression linked to cancer progression, immune modulation, and apoptosis. Interestingly, GZD824 showed potential synergy with immune checkpoint inhibitors, suggesting its suitability for combination therapies in advanced cases. While these results are encouraging, researchers caution that the findings are based on in vitro experiments. Translating these insights into clinical practice will require further validation in animal models and human trials to ensure safety and efficacy. If clinical trials confirm its promise, GZD824 could mark a significant advancement in the fight against endometrial cancer, offering hope to patients with limited options.